closed below lower BBs for only the 5th time in the last couple years Friday on some pretty "janky" headlines if you ask me about Henry A. Waxman (D-Beverly Hills) wants Gilead Sciences Inc
. to explain why it priced its new hepatitis C drug, Sovaldi, at $1,000 a pill. Considering nobody asked any questions about the targeted oncology drugs are even more and give people a whole 6-18 weeks efficacy over placebo in a rather miserable existance - seems odd to me the mouse man cares about a relatively effective Hep C drug that more or less cures people. Sometimes sectors that have experienced huge runs by any means necessary sell off but this is some mark ass stuff. Long.